BioPharma Dive - Latest News

Novo’s Wegovy successor disappoints in second large trial

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly surpass Eli Lilly’s Zepbound.

Mar 10, 2025 - 17:18
 0
Novo’s Wegovy successor disappoints in second large trial

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly surpass Eli Lilly’s Zepbound.

Read More

Tags:

Previous Article

Starboard CEO gets seat on Kenvue's board as activist investor, consumer health ...

Next Article

Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,...

Related Posts

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal ta...

Feb 9, 2025  0

Eikon raises $351M in one of the year’s largest biotech venture rounds

Eikon raises $351M in one of the year’s largest biotech...

Feb 26, 2025  0

CDC vaccine meeting, set to be first since RFK Jr. sworn in, is postponed

CDC vaccine meeting, set to be first since RFK Jr. swor...

Feb 20, 2025  0